

## H120-CNIO HAEMATOLOGICAL MALIGNANCIES CLINICAL RESEARCH UNIT

Joaquín Martínez-López  
Clinical Research Unit Head

Staff Scientists  
Lucía V. Fernández, Miguel Gallardo



### Clinical Scientists

Rosa Ayala, Teresa Cedena, María Calbacho, Javier de la Serna, Carlos Grande, Ana Jiménez, Pilar Martínez, Inmaculada Rapado, Antonia Rodríguez, Ricardo Sánchez, Beatriz Sanchez-Vega (until October)

### Post-Doctoral Fellows

Almudena García, Alejandra Leivas, María Linares, Antonio Valeri

### Graduate Students

Sergio Algar (since November), Isabel Cuenca, Jessica Encinas (since

November), Elena Maroto, Rebeca Mateos (February-October), M. Luz Morales, Alejandra Ortíz, Alba Rodríguez, Yanira Ruiz, Laura Sánchez

### Technicians

Pedro Aguilar (since March), Adrián

Fernández (since June), Irene García, Vanesa Garrido, Alexandra Juárez, Laura Moreno, Esther Onecha

### Students in Practice

Laura Carrasco (since November, UAH), Cristina Crespo (since November, UCM)

## OVERVIEW

The Haematological Malignancies Laboratory focuses on investigating novel drivers, biomarkers, diagnostic tools and therapeutic targets and approaches in haematological neoplasms such as myeloma and acute myeloid leukaemia.

Five main lines define our research project:

- Generation of mouse models focused on the molecule hnRNP K, a novel driver of lymphoma and leukaemia.
- Development of novel diagnostic and follow-up tools, such as minimal residual disease analysis in acute myeloid leukaemia (AML).
- Screening of novel drivers, biomarkers and therapeutic targets by next-generation-sequencing (NGS, e.g. exome sequencing of amyloidosis).
- Innovation of immunotherapy approaches. Generation of NK CARs and *in vitro/in vivo* validation.
- Novel therapeutic approaches. Screening of novel compounds (e.g. hnRNP K inhibitors) and pre-clinical trials of new drugs or drug combinations.

**“We have developed a strategy to identify undetectable levels of minimal residual disease using an NGS method, thereby improving the capacity to predict AML outcome over the current technical approaches.”**